124.  Sharifi-Rad, J.; Rapposelli, S.; Sestito, S.; Herrera-Bravo, J.; Arancibia-Diaz, A.; Salazar, L.A.; Yeskaliyeva, B.; Beyatli, A.; Leyva-Gómez, G.; González-Contreras, C.; Gürer, E.S.; Martorell, M.; Calina, D. Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation. J. Pers. Med. 2022, 12, 1515. doi:  10.3390/jpm12091515

​

123.  Ferrisi R, Gado F, Polini B, Ricardi C, Mohamed KA, Stevenson LA, Ortore G, Rapposelli S, Saccomanni G, Pertwee RG, Laprairie RB, Manera C, Chiellini G. Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R). Front Chem. 2022 Sep 27;10:984069. doi: 10.3389/fchem.2022.984069.  

​

122.  Gado F, Ferrisi R, Polini B, Mohamed KA, Ricardi C, Lucarini E, Carpi S, Domenichini F, Stevenson LA, Rapposelli S, Saccomanni G, Nieri P, Ortore G, Pertwee RG, Ghelardini C, Di Cesare Mannelli L, Chiellini G, Laprairie RB, Manera C. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands. J Med Chem. 2022 Jul 28;65(14):9918-9938. doi: 10.1021/acs.jmedchem.2c00582. Epub 2022 Jul 18. PMID: 35849804..

​

121.  Riveiro ME,  Huguet S,  Vazquez R,  Frapolli R,  Puricelli G, Sestito S,  Madar O, Rezai K, Garau G, Rapposelli S. Abstract 2569: Development of potent dual PDK1/AurA kinase inhibitors for Ewing sarcoma therapy. Cancer Res 15 June 2022; 82 (12_Supplement): 2569. https://doi.org/10.1158/1538-7445.AM2022-2569

​

120. Bacci A, Corsi F, Runfola M, Sestito S, Piano I, Manera C, Saccomanni G, Gargini C, Rapposelli S. Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids. Pharmaceuticals. 2022; 15(6):688. https://doi.org/10.3390/ph15060688

​

119. Gado F, Ferrisi R, Di Somma S, Napolitano F, Mohamed KA, Stevenson LA, Rapposelli S, Saccomanni G, Portella G, Pertwee RG, Laprairie RB, Malfitano AM, Manera C. Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells. Molecules. 2022 27(9):3019. https://doi.org/10.3390/molecules27093019

​

118. Rapposelli S, Gaudio E, Bertozzi F, Gul S. Editorial: Protein-Protein Interactions: Drug Discovery for the Future. Front Chem. 2021 Nov 29;9:811190. doi: 10.3389/fchem.2021.811190. PMID: 34912787; PMCID: PMC8666435.

 

117.Caddeo A, Kowalik MA, Serra M, Runfola M, Bacci A, Rapposelli S, Columbano A, Perra A. TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD. Int J Mol Sci. 2021 Dec 3;22(23):13105. doi: 10.3390/ijms222313105.

 

116. Perra, A., Kowalik, M. A., Serra, M., Runfola, M., Rapposelli, S., & Columbano, A. (2021, July). Novel liver-specific thyromimetics for the treatment of steatohepatitis. In JOURNAL OF HEPATOLOGY (Vol. 75, pp. S627-S627). RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS: ELSEVIER.

 

115. Taheri Y, Sharifi-Rad J, Antika G, Yılmaz YB, Tumer TB, Abuhamdah S, Chandra S, Saklani S, Kılıç CS, Sestito S, Daştan SD, Kumar M, Alshehri MM, Rapposelli S, Cruz-Martins N, Cho WC. Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits. Oxid Med Cell Longev. 2021 Sep 20;2021:1987588. doi: 10.1155/2021/1987588. PMID: 34594472; PMCID: PMC8478534.

 

114. Runfola M, Perni M, Yang X, Marchese M, Bacci A, Mero S, Santorelli FM, Polini B, Chiellini G, Giuliani D, Vilella A, Bodria M, Daini E, Vandini E, Rudge S, Gul S, Wakelam MOJ, Vendruscolo M, Rapposelli S. Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer's Disease. Pharmaceuticals (Basel). 2021 Dec 19;14(12):1330. doi: 10.3390/ph14121330. PMID: 34959730; PMCID: PMC8704018.

 

113. Sestito S, Bacci A, Chiarugi S, Runfola M, Gado F, Margheritis E, Gul S, Riveiro ME, Vazquez R, Huguet S, Manera C, Rezai K, Garau G, Rapposelli S. Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile. Eur J Med Chem. 2021 Dec 15;226:113895. doi: 10.1016/j.ejmech.2021.113895. 

​

112. B Kim, Y H Ko, M Runfola, S Rapposelli, G Ortore, G Chiellini, J H Kim Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis Int. J. Mol. Sci. 2021, 22(7), 3488;  doi:10.3390/ijms22073488

​

111. J Sharifi-Rad, C Quispe, M Butnariu, L S Rotariu, O Sytar, S Sestito, S Rapposelli, M Akram, M Iqbal, A Krishna, N V A Kumar, S S Braga, S M Cardoso, K Jafernik, H Ekiert, N Cruz-Martins, A Szopa, M Villagran, L Mardones, M Martorell, A O Docea, D Calina Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment Cancer Cell International 2021: 21 (1), 1-21 doi:10.1186/s12935-021-02025-4

​

110. M E Riveiro, S Rapposelli, S Huguet, R Vazquez, M Bekradda, G Puricelli, S Sestito, O Madar, K Rezai Dual targeting of PDK1 and Aurora A using first-in class OXID-pyridonyl compounds in preclinical models of Ewing sarcoma Cancer Research 2021: 81 (13 Supplement), 1294-1294  doi:10.1158/1538-7445.AM2021-1294

 

109. A Bacci, M Runfola, S Sestito, S Rapposelli. Beyond Antioxidant Effects: Nature-Based Templates Unveil New Strategies for Neurodegenerative Diseases Antioxidants 2021:10(3), 367  doi:10.3390/antiox10030367

​

108. Testai L, Sestito S, Martelli A, Gorica E, Flori L, Calderone V, Rapposelli S. Synthesis and pharmacological characterization of mitochondrial KATP channel openers with enhanced mitochondriotropic effects Bioorganic Chemistry 2021, 107, 104572  doi:10.1016/j.bioorg.2020.104572

​

107. Costa J, Almonti V, Cacopardo L, Poli D, Rapposelli S, Ahluwalia A. Investigating Curcumin/Intestinal Epithelium Interaction in a Millifluidic Bioreactor. Bioengineering 2020, 7, 100 doi:10.3390/bioengineering7030100

 

106. Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, Sestito S, Rapposelli S, Neffe-Skocińska K, Zielińska D, Salehi B, Setzer WN, Dosoky NS, Taheri Y, El Beyrouthy M, Martorell M, Ostrander EA, Suleria HAR, Cho WC, Maroyi A, Martins N. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Front Pharmacol. 2020;11:01021. doi: 10.3389/fphar.2020.01021.

​

105. Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders Front. Med.,2020 doi:10.3389/fmed.2020.00331

 

104. Gütschow M, Eynde JJV, Jampilek J, Kang C, Mangoni AA, Fossa P, Karaman R, Trabocchi A, Scott PJH, Reynisson J, Rapposelli S, Galdiero S, Winum JY, Brullo C, Prokai-Tatrai K, Sharma AK, Schapira M, Azuma YT, Cerchia L, Spetea M, Torri G, Collina S, Geronikaki A, García-Sosa AT, Vasconcelos MH, Sousa ME, Kosalec I, Tuccinardi T, Duarte IF, Salvador JAR, Bertinaria M, Pellecchia M, Amato J, Rastelli G, Gomes PAC, Guedes RC, Sabatier JM, Estévez-Braun A, Pagano B, Mangani S, Ragno R, Kokotos G, Brindisi M, González FV, Borges F, Miloso M, Rautio J, Muñoz-Torrero D.Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7. Molecules.2020 Jun 28;25(13):E2968. doi: 10.3390/molecules25132968.

​

103. Perra A, Kowalik MA, Cabras L, Runfola M, Sestito S, Migliore C, Giordano S, Chiellini G, Rapposelli S, Columbano A. Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration. (2020) Cell Prolif. e12808.  DOI: 10.1111/cpr.12808

​

102. Salehi B, Konovalov DA, Fru P, Kapewangolo P, Peron G, Ksenija MS, Cardoso SM, Pereira OR, Nigam M, Nicola S, Pignata G, Rapposelli S, Sestito S, Anil Kumar NV, de la Luz Cádiz-Gurrea M, Segura-Carretero A, P Mishra A, Sharifi-Rad M, C Cho W, Taheri Y, Setzer WN, Sharifi-Rad J. Areca catechu-From farm to food and biomedical applications. (2020) Phytother Res.  DOI: 10.1002/ptr.6665..

​

101.Bellusci L, Runfola M, Carnicelli V, Sestito S, Fulceri F, Santucci F, Lenzi P, Fornai F, Rapposelli S, Origlia N, Zucchi R, Chiellini G. Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents Through the Modulation of SIRT6. (2020) Molecules;25(5). DOI: 10.3390/molecules25051054

​

100. Runfola M, Sestito S, Gul S, Chiellini G, Rapposelli S. Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics (2020) Data in Brief 29: 105206. DOI: 10.1016/j.dib.2020.105206

​

99. Runfola M, Sestito S, Bellusci L, La Pietra V, D'Amore VM, Kowalik MA, Chiellini G, Gul S, Perra A, Columbano A, Marinelli L, Novellino E, Rapposelli S. Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis. (2020) Eur J Med Chem. 188: 112006. DOI: 10.1016/j.ejmech.2019.112006

​

98. Casari I, Domenichini A, Sestito S, Capone E, Sala G, Rapposelli S, Falasca M. Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation. Cancers  (Basel) (2019). 11(11). pii: E1695. DOI: 10.3390/cancers11111695

​

97.  Sestito S, Pruccoli L, Runfola M, Citi V, Martelli A, Saccomanni G, Calderone V, Tarozzi A, Rapposelli S.. Design and synthesis of H2S-donor hybrids: A new treatment for Alzheimer's disease? (2019)  Eur J Med Chem. 184:111745;.

DOI: 10.1016/j.ejmech.2019.111745

​

96.  Rogowski M,  Bellusci L,  Sabatini M,  Rapposelli S,  Rahman SM,  Chiellini G, Assadi-Porter FM. Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway (2019)  Int. J. Mol. Sci. 20, 4054;.

DOI: 10.3390/ijms20164054

​

95.  Emmanouilidi A, Fyffe CA, Ferro R, Edling CE, Capone E, Sestito S, Rapposelli S, Lattanzio R, Iacobelli S, Sala G, Maffucci T, Falasca M. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. (2019)  J Exp Clin Cancer Res 38(1):191. DOI: 10.1186/s13046-019-1191-2.

​

94.  Oliveira LC, Marques MP, Caseiro AJ, Rapposelli S, Batista-de-Carvalho AL, Fonseca AP. A novel approach in glioblastoma multiforme drug discovery: perturbation studies in vitro. (2019)  J Appl Pharm Sci 9(04):058–065.

DOI: 10.7324/JAPS.2019.90407.

​

93.  Sestito S, Wang S, Chen Q, Lu J, Bertini S, Pomelli C, Chiellini G, He X, Pi R, Rapposelli S. Multi-targeted ChEI-copper chelating molecules as neuroprotective agents. (2019)  Eur J Med Chem 174:216-225.

DOI: 10.1016/j.ejmech.2019.04.060.

​

92.  Sestito S,  Rapposelli S. A patent update on PDK1 inhibitors (2015-present). (2019)  Expert Opinion on Therapeutic Patents. 29(4):271-82..

DOI: 10.1080/13543776.2019.1597852

 

91.  Sestito S, Daniele S, Pietrobono D, Citi V, Bellusci L, Chiellini G, Calderone V, Martini C, Rapposelli S. Memantine prodrug as a new agent for Alzheimer's Disease. (2019)  Sci Rep.;9(1):4612.

DOI: 10.1038/s41598-019-40925-8

 

90.  Alcaro S, Bolognesi ML,  García-Sosa AT,  Rapposelli S. Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation. (2019)  Frontiers in Chemistry 7:71

DOI: 10.3389/fchem.2019.00071

​

89. Salehi B, Sestito S, Rapposelli S, Peron G, Calina D, Sharifi-Rad M, Sharopov F, Martins N, Sharifi-Rad J. Epibatidine: A Promising Natural Alkaloid in Health. (2018) Biomolecules;9(1). pii: E6.

DOI: 10.3390/biom9010006.

 

88. Nyein C M,  Zhong X, Lu J, Luo H, Wang J, Rapposelli S, Li M,  Ou-yang Y, Pi R, He X. Synthesis and anti-glioblastoma effects of artemisinin-isothiocyanate derivatives. (2018) RSC Advances 8 (71), pp. 40974-40983.

DOI: 10.1039/C8RA08162J

 

87.  Sestito S, Runfola M, Tonelli M, Chiellini G, Rapposelli S. New multitarget approaches in the war against Glioblastoma: a mini-perspective (2018) Front. Pharmacol. 9:874.

DOI: 10.3389/fphar.2018.00874

​

86.  Zhang X, He X, Chen Q, Lu J, Rapposelli S, Pi R. A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimer's disease (2018) Bioorganic and Medicinal Chemistry, 26 (3), pp. 543-550

DOI: 10.1016/j.bmc.2017.12.042

​

85. Bellusci L, Laurino A, Sabatini M, Sestito S, Lenzi P, Raimondi L, Rapposelli S, Biagioni F, Fornai F, Salvetti A, Rossi L, Zucchi R, Chiellini G. New insights into the potential roles of 3-Iodothyronamine (T1AM) and newly developed thyronamine-like TAAR1 agonists in neuroprotection (2017) Frontiers in Pharmacology, 8

DOI: 10.3389/fphar.2017.00905

​

84. Sestito S, Nesi G, Pi R, Macchia M, Rapposelli S. Hydrogen sulfide: a worthwhile tool in the design of new multitarget drugs. (2017) Frontiers in chemistry 5, 72

DOI:10.3389/fchem.2017.00072

​

83. Nesi G, Chen Q, Sestito S, Digiacomo M, Yang X, Wang S, Pi R, Rapposelli S. Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease. (2017) BIOORG. MED. CHEM. LETTERS 27(21) pp.4812-6

DOI: 10.1016/j.ejmech.2017.10.006

​

82. Bertini S, Ghilardi E, Asso V, Minutolo F, Rapposelli S, Digiacomo M, Saccomanni G, Salmaso V, Sturlese M, Moro S. Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors. (2017) Eur. J. Med Chem, 141, pp.232-239.

DOI: 10.1016/j.bmcl.2017.09.058

​

81. Nesi G, Sestito S, Digiacomo M, Rapposelli S. Oxidative stress, mitochondrial abnormalities and proteins deposition: multitarget approaches in Alzheimer's disease. (2017) Current topics in medicinal chemistry. 17(27), pp. 3062-79.

DOI: 10.2174/1568026617666170607114232

 

80. Rapposelli S, Gambari L, Digiacomo M, Citi V, Lisignoli G, Manferdini C, Calderone V, Grassi F. A Novel H2S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions (2017) Scientific Reports, 7 (1), art. no. 11940

DOI: 10.1038/s41598-017-11608-z

​

79. Daniele S, Sestito S, Pietrobono D, Giacomelli C, Chiellini G, Di Maio D, Marinelli L, Novellino E, Martini C, Rapposelli S. Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells. ACS Chem Neurosci. 2017 Jan 18;8(1):100-114.

DOI: 10.1021/acschemneuro.6b00251.

​

78. Digiacomo M, Sartini S, Nesi G, Sestito S, Coviello V, La Motta C, Rapposelli S. Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors Bearing a Spirobenzopyran Scaffold. Open Med Chem J. 2017 Jan 31;11:9-23.

DOI: 10.2174/1874104501711010009

​

77. Chen Z, Digiacomo M, Tu Y, Gu Q, Wang S, Yang X, Chu J, Chen Q, Han Y, Chen J, Nesi G, Sestito S, Macchia M, Rapposelli S, Pi R, Discovery of novel rivastigminehydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease, European Journal of Medicinal Chemistry 2017 Jan 5;125:784-792.

DOI: 10.1016/j.ejmech.2016.09.052

 

76. Chiellini G, Nesi G, Sestito S, Chiarugi S, Runfola M, Espinoza S, Sabatini M, Bellusci L, Laurino A, Cichero E, Gainetdinov RR, Fossa P, Raimondi L, Zucchi R, Rapposelli S. Hit-to-lead optimization of mouse Trace Amine Associated Receptor 1 (mTAAR1) agonists with a diphenylmethane-scaffold: Design, Synthesis, and biological study. J Med Chem. 2016 Oct 12.

DOI: 10.1021/acs.jmedchem.6b01092

 

75. Gonca E, Rapposelli S, Darıcı F, Digiacomo M, Yılmaz Z. Antiarrhythmic activity of a new spiro-cyclic benzopyran activator of the cardiac mitochondrial ATP dependent potassium channels. Arch Pharm Res. 2016 Sep;39(9):1212-22.

DOI: 10.1007/s12272-016-0779-8

​

74.  Petroni D, Bartoli A, Rapposelli S, Digiacomo M, Burchielli S, Nesi G, Lapucci A, Pardini S, Fucci S, Macchia M, Salvadori PA, Menichetti L. Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein. Mol Imaging Biol. 2016 May 27.

DOI: 10.1007/s11307-016-0965-6

​

73. Sestito S, Daniele S, Nesi G, Zappelli E, Di Maio D, Marinelli L, Digiacomo M, Lapucci A, Martini C, Novellino E, Rapposelli S. Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another Tools to Fight Glioblastoma European Journal of Medicinal Chemistry  (2016), 118, 47-63

DOI: 10.1016/j.ejmech.2016.04.003

​

72. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Breschi M, Macchia M, Martini C, Rapposelli S. (2015) Design and synthesis of 2-oxindole multi-targeted inhibitors of PDK1/Akt Signaling Pathway for the treatment of Glioblastoma multiforme European journal of medicinal chemistry, 105:274-288

DOI: 10.1016/j.ejmech.2015.10.020

​

71. Chiellini G, Nesi G, Digiacomo M, Malvasi R, Espinoza S, Sabatini M, Frascarelli S, Laurino A, Cichero E, Macchia M, Gainetdinov RR, Fossa P, Raimondi L, Zucchi R, Rapposelli S. (2015) Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists. J Med Chem.58(12):5096-107.

DOI: 10.1021/acs.jmedchem.5b00526.

 

70. Daniele S, Costa B, Zappelli E, Da Pozzo E, Sestito S, Nesi G, Campiglia P, Marinelli L, Novellino E, Rapposelli S, Martini C (2015) Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep. (5):9956.

DOI: 10.1038/srep09956

​

69. Digiacomo M,  Chen Z, Wang S, Lapucci A, Macchia M, Yang X, Chu J, Han Y, Pi R, Rapposelli S. (2015) Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD Bioorg Med Chem Lett. 25, 807-810

DOI: 10.1016/j.bmcl.2014.12.084

​

68. Testai L, Rapposelli S, Martelli A, Breschi MC, Calderone V. Mitochondrial potassium channels as pharmacological target for cardioprotective drugs (2015) Medicinal Research Reviews 35 (3) pp. 520 – 553

DOI: 10.1002/med.21332

​

67. Digiacomo M, Martelli A, Testai L, Lapucci A, Breschi MC,  Calderone V, Rapposelli S. (2015). Synthesis and evaluation of multi-functional NO-donor/ insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications. Bioorg Med Chem 23, 422-428

DOI: 10.1016/j.bmc.2014.12.043

​

66. Nesi G, Colabufo NA, Contino M, Perrone MG, Digiacomo M, Perrone R, Lapucci A, Macchia M, Rapposelli S. (2014). SAR study on arylmethyloxyphenyl scaffold: Looking for a P-gp nanomolar affinity. Eur. J. Med Chem. 76:558-566

DOI: 10.1016/j.ejmech.2014.02.051

​

65. Nesi G, Sestito S, Mey V, Ricciardi S, Falasca M, Danesi R, Lapucci A, Breschi MC, Fogli S, Rapposelli S. (2013) Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer ACS Medicinal Chemistry Letters, 4 (12):1137–1141

DOI: 10.1021/ml400162g

​

64. Martelli A, Testai L, Citi V, Marino A, Pugliesi I, Barresi E, Nesi G, Rapposelli S, Taliani S, Da Settimo F, Breschi MC, Calderone V. (2013) Arylthioamides as H2S Donors: L-​Cysteine-​Activated Releasing Properties and Vascular Effects in Vitro and in Vivo ACS Medicinal Chemistry Letters 4(10):904-908

DOI: 10.1021/ml400239a

​

63. Zhu D, Chen M, Li M, Luo B, Zhao Y, Huang P, Xue F, Rapposelli S, Pi R, Wen S. (2013) Discovery of novel N-substituted carbazoles as neuroprotective agents with potent anti-oxidative activity. Eur J Med Chem. 68C:81-88.

DOI: 10.1016/j.ejmech.2013.07.029

 

62. Huang W-Y, Chao X-J, Ouyang Y, Liu A-M, He X-X, Chen M-H, Wang L-H, Liu J, Yu S-W, Rapposelli S, Pi R (2012). Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer Against Alzheimer's Disease, Prevents Oxidative Stress-Induced Neuronal Death Through Activating Nrf2/ARE/HO-1 Pathway in HT22 Cells . CNS Neurosciences and Therapeutics 18:950-952.

DOI: 10.1111/cns.12286

​

61. Chao XJ, He XX, Yang YL, Zhou X, Jin MH, Liu S, Cheng ZY, Liu PQ, Wang YT, Yu JC, Tan Y, Huang YJ, Qin J, Rapposelli S, Pi RB (2012). Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem Lett.,  22:6498-6502

DOI: 10.1016/j.bmcl.2012.08.036

​

60. Rapposelli S, Coi A, Imbriani M, Bianucci AM (2012). Development of classification models for identifying "true" P-glycoprotein (P-gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays. International Journal of Molecular Sciences, 13:6924-6943.

DOI: 10.3390/ijms13066924

 

59. Chiellini G, Rapposelli S, Zhu J, Massarelli I, Saraceno M, Bianucci AM, Plum LA., Clagett-Dame M, DeLuca H F. (2012), Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase. Steroids, 77(3): 212-23.

DOI: 10.1016/j.steroids.2011.11.007

​

58. Rapposelli S, Da Settimo F, Digiacomo M, La Motta C, Lapucci A, Sartini S, Vanni M. (2011) Synthesis and Biological Evaluation of 2'-Oxo-2,3-dihydro-3'H- spiro[chromene-4,5'-[1,3]oxazolidin]-3'yl]acetic Acid Derivatives as Aldose Reductase Inhibitors. Arch Pharm (Weinheim). 344(6), 372-385

DOI: 10.1002/ardp.201000302

​

57. Rapposelli S. (2011)  The Importance of Stereochemistry in Medicinal Chemistry and Drug Discovery. Curr Top Med Chem. 11(7); 758-759 (Editorial)

DOI: 10.2174/156802611795165179

​

56. Rapposelli S. (2011) Novel ATP-sensitive potassium channel ligands: a patent overview (2005-2010).  Expert Opinion on therapeutic patents, 21(3), 355-379.  

DOI: 10.1517/13543776.2011.553601

​

55. Rapposelli S, Breschi MC, Calderone V, Digiacomo M, Martelli A, Testai L, Vanni M, Balsamo A. (2011) Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia. European Journal of Medicinal Chemistry  ,  46(3),  966-973.

DOI: 10.1016/j.ejmech.2011.01.003

​

54. Coi A, Bianucci AM, Rapposelli S, Balsamo A. (2010),  Classification models for the identification of P-gp inhibitors. Drugs of the Future, 35(suppl. A), abstract

http://hdl.handle.net/11568/140752

.

53. Rapposelli S, Digiacomo M, Franchi S, Moretti S, Pinza  M, Sacerdote P, Balsamo A. (2010),  Sodium N-(methylsulfonyl)-N-(4-nitro-2-phenoxyphenyl)sulfamate: a water-soluble nimesulide prodrug for parenteral use. Molecular Pharmaceutics, 7(5), 1871–1876,

DOI: 10.1021/mp1001137

​

52. Calderone V, Testai L, Martelli A, Rapposelli S, Digiacomo M, Balsamo A, Breschi MC (2010), Anti-ischemic properties of a new spiro-cyclic benzopyran activator of the cardiac mitoKATP channel. Biochem. Pharmacol. 79, 39-47

DOI: 10.1016/j.bcp.2009.07.017

​

51. Rapposelli S, Calderone V, Digiacomo M, Martelli A, Minutolo F, Testai L, Balsamo A. (2009) Spiro-benzopyran structure: a new scaffold for cardioprotection. Drugs of the future, 34 (suppl A), 73 (Abstract).

http://hdl.handle.net/11568/196773

​

50. Calderone V, Rapposelli S, Martelli A, Digiacomo M, Testai L, Torri S, Marchetti P, Breschi MC, Balsamo A. (2009), NO-glibenclamide derivatives: Prototypes of a new class of nitric oxide-releasing anti-diabetic drugs. Bioorg. Med. Chem. 17 5426–5432

DOI: 10.1016/j.bmc.2009.06.049

​

49. Coi A, Bianucci AM, Calderone V, Testai L, Digiacomo M, Rapposelli S, Balsamo A. (2009) Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers Bioorg. Med. Chem. 17 5565–5571.

DOI: 10.1016/j.bmc.2009.06.028

​

48. Rapposelli S, Calderone V, Cirilli R, Digiacomo M, Faggi C, La Torre F, Manganaro M, Martelli A., Testai L. (2009),  Enantioselectivity in Cardioprotection induced by (S)-(−)-2,2-Dimethyl-N-(4′-acetamido-benzyl)-4-spiromorpholone-chromane J. Med. Chem. 2(5), 1477-1480.

DOI: 10.1021/jm801459f

​

47. Rapposelli S, Digiacomo M, Balsamo A. (2009), P-gp Transporter and its Role in Neurodegenerative Diseases. Curr Top Med Chem. 9(1), 209-17.

DOI: 10.2174/156802609787521544

​

46. Minutolo F, Bertini S, GranchiC, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA, Macchia M. (2009) Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor b.  J. Med. Chem.,  52(3), 858-867

DOI: 10.1021/jm801458t

​

45. Colabufo NA, Berardi F, Perrone R, Rapposelli S, Digiacomo M, Vanni M, Balsamo A. (2008) 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J. Med. Chem., 51(23), 7602-7613

DOI: 10.1021/jm800928j

​

44. Breschi MC, Calderone V, Digiacomo M, Manganaro M, Martelli A, Minutolo F, Rapposelli S, Testai L, Tonelli F, Balsamo A. (2008), Spirocyclic Benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel. J. Med. Chem. 51(21), 6945-6954.

DOI: 10.1021/jm800956g

​

43. Asso V, Ghilardi E, Bertini S, Digiacomo M, Granchi C, Minutolo F, Rapposelli S, Bartolato A, Moro S, Macchia M. (2008) Alpha-Naphthylaminopropan-2-ol derivatives as BACE1 inhibitors. ChemMedChem  ,  3(10),  1530-1534.

DOI: 10.1002/cmdc.200800162

​

42. Torri S, Galli M, Calderone V, Rapposelli S, Digiacomo M, Martelli A, Lupi R, Del Guerra S, Bugliani M, Mancarella R, D'Aleo V, Boggi U, Balsamo A. (2008) Pharmacodynamic hybrids with insulin secretagogue and NO-Donor activity. DIABETES 57, A584, abstract (ISSN 0012-1797)

http://hdl.handle.net/11568/126168

​

41. Rapposelli S, Cuboni S, Digiacomo M, Lucacchini A,  Minutolo F, Trincavelli ML, Balsamo, A. (2008) Synthesis and Affinity Evaluation for AT1 Receptor of Phenylsalicylaldoxime-Derivatives Structurally Related to Sartans, Heterocycles, 75(6), 1467-1478

DOI: 10.3987/COM-07-11309

​

40. Rapposelli S, Cuboni S, Digiacomo M.; Lapucci, A.; Trincavelli, Maria L.; Tuccinardi, T.; Balsamo, A. (2008) Synthesis and AT1 affinity evaluation of benzamidophenyl analogs of known AT1 receptor ligands with similar aromatic skeleton  ARKIVOC (Gainesville, FL, United States), ii, 268-286

http://www.arkat-usa.org/get-file.php?fileid=23351

​

39. Minutolo F, Bellini R, Bertini S, Carboni I, Lapucci A, Pistolesi L, Prota G, Rapposelli S, Solati F, Tuccinardi T, Martinelli A, Stossi F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Macchia M. (2008) Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor J. Med. Chem., 51, 1344–1351

DOI: 10.1021/jm701396g

​

38. Colabufo NA, Berardi F,  Perrone R, Rapposelli S, Digiacomo M, Vanni M, Balsamo A. (2008) Synthesis and Biological Evaluation of (Hetero)Arylmethyloxy- and Arylmethylamine-phenyl Derivatives as Potent P-glycoprotein Modulating Agents. J. Med. Chem. 51, 1415-1422.

DOI: 10.1021/jm701267q

​

37. Calderone V, Digiacomo M, Martelli A, Minutolo F, Rapposelli S, Testai L, Balsamo A. (2008) Evaluation of the NO-releasing properties of NO-donor linkers  J.Pharm.Pharmacol., 60(2), 189-195

DOI: 10.1211/jpp.60.2.0007

​

36. Balsamo A, Calderone V, Rapposelli S. (2008) New Emerging Prospects in the Pharmacotherapy of Hypertension  Cardiovasc Hematol Agents Med Chem., 6(1), 1-19. Review.

DOI: 10.2174/187152508783329993

​

35. Torri S, Galli M, Calderone V, Rapposelli S, Digiacomo M, Martelli A, D'Aleo V, Boggi U, Balsamo A, Marchetti P.(2007) In-vitro evaluation of new pharmacodynamic hybrids with insulin secretagogue and NO-donor activity DIABETOLOGIA 50, S374, abstract (ISSN 0012-186X)

http://hdl.handle.net/11568/117623

​

34. Calderone V, Testai L, Martelli A, Rapposelli S, Breschi MC. (2007) Activators of cardiac mitochondrial ATP-sensitive potassium channels: promising drugs for anti-ischaemic therapy. Curr Topics Pharmacol., 11(1), 81-90. Review

​

​

33. Orlandini E, Rapposelli S, Nencetti S, Giannaccini G, Betti L, Balsamo A. (2007) Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oximes. Arch Pharm (Weinheim), 340(3), 135-139.

DOI: 10.1002/ardp.200600123

​

32. Testai L, Rapposelli S, Calderone V. (2007) Cardiac ATP-sensitive potassium channels, a potential target for an anti-ischaemic pharmacological strategy. Cardiovasc Haematol Agents Med Chem, 5, 79-90. Review.

DOI: 10.2174/187152507779315831

​

31. Breschi MC, Calderone V, Martelli A, Minutolo F, Rapposelli S, Testai L, Tonelli F, Balsamo A. (2006) New benzopyran-based openers of the mitochondrial KATP potassium channel with potent anti-ischaemic properties. J. Med. Chem.,  49, 7600-7602.

DOI: 10.1021/jm061228l

​

30. Colabufo NA, Berardi F, Perrone R,  Rapposelli S, Digiacomo M, Balsamo A. (2006) Arylmethyloxyphenyl Derivatives: Small Molecules Displaying P-Glycoprotein Inhibition. J. Med. Chem.  ,  49(22),  6607-6613.

DOI: 10.1021/jm060639z

​

29. Minutolo F, Bertini S, Martinelli A, Ortore G, Placanica G, Prota G, Rapposelli S, Tuccinardi T, Sheng S, Carlson KE, Katzenellenbogen BS,  Katzenellenbogen JA, Macchia M. (2006) Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands.    ARKIVOC (Gainesville, FL, United States), 8,  83-94. 

​​

28. Tuccinardi T, Bertini S, Martinelli A, Minutolo F, Ortore G, Placanica G, Prota G, Rapposelli S, Carlson KE, Katzenellenbogen JA, Macchia M. (2006) Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes. J. Med. Chem.,  49(16),  5001-5012. 

DOI: 10.1021/jm060560u

​

27. Tuccinardi T, Calderone V, Rapposelli S, Martinelli A. (2006) Proposal of a New Binding Orientation for Non-Peptide AT1 Antagonists: Homology Modeling, Docking and Three-Dimensional Quantitative Structure-Activity Relationship Analysis. J. Med. Chem.,  49(14),  4305-4316.

DOI: 10.1021/jm060338p

​

26. Breschi MC, Calderone V, Digiacomo M, Macchia M, Martelli A, Martinotti E, Minutolo F, Rapposelli S, Rossello A, Testai L, Balsamo A.  (2006)  New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design, Synthesis, and Biopharmacological Properties.  J. Med. Chem.,  49(8),  2628-2639. 

DOI: 10.1021/jm0600186

​

25. Martelli A, Rapposelli S, Calderone V. (2006) NO-releasing hybrids of cardiovascular drugs.  Curr. Med. Chem.,  13(6),  609-625. 

DOI: 10.2174/092986706776055634

​

24. Minutolo F, Bertini S, Betti L, Danesi R, Gervasi G, Giannaccini G, Martinelli A, Papini AM, Peroni E, Placanica G, Rapposelli S, Tuccinardi T, Macchia M. (2006) Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition. ChemMedChem,  1(2),  218-224.

DOI: 10.1002/cmdc.200500010

 

 

23. Minutolo F, Sala G, Bagnacani A, Bertini S, Carboni I, Placanica G, Prota G, Rapposelli S, Sacchi N, Macchia M, Ghidoni R.   (2005) Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells. J.Med. Chem. ,  48(22),  6783-6786.

DOI: 10.1021/jm050528k

 

22. Minutolo, F, Asso, V, Bertini, S, Betti, L, Ciriaco, M, Danesi, R, Gervasi, G, Ghilardi, E, Giovanetti, E, Giannaccini, G, Placanica, G, Prota, G, Rapposelli S, Macchia, M. (2005)   Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents. Med. Chem.  ,  1(3),  239-244.

DOI: 10.2174/1573406053765512t

 

21. Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson S.J, Murphy G, Balsamo A. (2005) A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg. Med. Chem. Lett.,  15(9),  2311-2314.

DOI: 10.1016/j.bmcl.2005.03.002

 

20. Minutolo F, Antonello M, Barontini S, Bertini S, Betti L, Danesi R, Gervasi G, Giannaccini G, Papi C, Placanica G, Rapposelli S, Macchia M.  Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors. Farmaco,   59(11),  887-892.

DOI: 10.1016/j.farmac.2004.08.002

 

19. Minutolo F, Asso V, Bertini S, Betti L, Gervasi G, Ghilardi E, Giannaccini G, Placanica G, Prota G, Rapposelli S, Macchia M. (2004) Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase. Farmaco,  59(11),  857-861.  

DOI: 10.1016/j.farmac.2004.06.003

 

18. Breschi M.C, Calderone V, Digiacomo M, Martelli A, Martinotti E, Minutolo F, Rapposelli S, Balsamo A. (2004) NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs. J. Med. Chem.,  47(23),  5597-5600. 

DOI: 10.1021/jm049681p

 

17. Rossello A, Orlandini E, Nuti E, Rapposelli S, Macchia M, Di Modugno E, Balsamo A. (2004) Synthesis and antimicrobial activity of new 7b- (benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins. Farmaco,  59(9),  691-696. 

DOI: 10.1016/j.farmac.2004.05.001

 

16. Minutolo F, Antonello M, Bertini S, Placanica G, Rapposelli S, Carlson K. E, Katzenellenbogen J. A, Macchia M. (2004) Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands.  Farmaco,  59(8),  601-607. 

DOI: 10.1016/j.farmac.2004.01.007

 

15. Rossello A, Nuti E, Orlandini E, Carelli P, Rapposelli S, Macchia M, Minutolo F, Carbonaro L, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A. (2004) New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg. Med. Chem.,  12(9),  2441-2450. 

DOI: 10.1016/j.bmc.2004.01.047

 

14. Rapposelli S, Lapucci A, Minutolo F, Orlandini E, Ortore G, Pinza M, Balsamo A. (2004) Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs. Farmaco,  59(1),  25-31. 

DOI: 10.1016/j.farmac.2003.09.003

 

13. Minutolo F, Bertini S, Betti L, Danesi R, Gervasi G, Giannaccini G, Papi C, Placanica G, Barontini S, Rapposelli S, Macchia M. (2003) Stable analogs of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. Bioorg. Med. Chem. Lett.,  13(24),  4405-4408.

DOI: 10.1016/j.bmcl.2003.09.035

 

12. Minutolo F, Bertini S, Betti L, Di Bussolo V, Giannaccini G, Placanica G, Rapposelli S, Spielmann H. P, Macchia M. (2003) Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity. Farmaco, 58(12),  1277-1281.  

DOI: 10.1016/j.farmac.2003.08.002

 

11. Balsamo A, Mancini F, Milanese C, Orlandini E, Ortore G, Pinza M, Rapposelli S, Rossello A. (2003) Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion. Farmaco ,  58(9),  707-714.  

DOI: 10.1016/S0014-827X(03)00110-1

 

10. Minutolo F, Antonello M, Bertini S, Ortore G, Placanica G, Rapposelli S, Sheng S, Carlson K. E, Katzenellenbogen B. S, Katzenellenbogen J. A, Macchia M. (2003) Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure: Role of the Phenol-Type Pseudocycle in the Binding Process. J. Med. Chem. ,  46(19),  4032-4042.  

DOI: 10.1021/jm0308390

 

9. Minutolo F, Antonello M, Bertini S, Rapposelli S, Rossello A, Sheng S, Carlson K. E, Katzenellenbogen J. A, Macchia M. (2003)  Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-Substituted 3,4-Diarylsalicylaldoximes on estrogen receptors a  and b. Bioorg. Med. Chem.  11(7),  1247-1257.

DOI: 10.1016/S0968-0896(02)00640-5

 

8. Macchia M, Bertini S, Fogli S, Giovannetti E, Minutolo F, Rapposelli S, Danesi R. (2003)   Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Farmaco  ,  58(3),  205-211.

DOI: 10.1016/S0014-827X(03)00015-6

 

7. Balsamo A, Coletta I, Guglielmotti A, Landolfi C, Mancini F, Martinelli A, Milanese C, Minutolo F, Nencetti S, Orlandini E, Pinza M, Rapposelli S, Rossello A. (2003) Synthesis of heteroaromatic analogs of (2-aryl-1-cyclopentenyl-1-alkylidene) (arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring. Eur. J. Med. Chem., 38(2),  157-168.

DOI: 10.1016/S0223-5234(02)01448-4

 

6. Macchia M, Antonello M, Bertini S, Di Bussolo V, Fogli S, Giovannetti E, Minutolo F, Rapposelli S, Danesi R. (2003) Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. Farmaco, 58(1),  85-89. 

DOI: 10.1016/S0014-827X(02)00002-2

 

5. Rossello, A, Bertini, S, Lapucci, A, Macchia, M, Martinelli, A, Rapposelli, S, Herreros, E, Macchia, B. (2002) Synthesis, Antifungal Activity, and Molecular Modeling Studies of New Inverted Oxime Ethers of Oxiconazole. J. Med. Chem. , 45(22),  4903-4912.

DOI: 10.1021/jm020980t

 

4. Balsamo, A, Coletta, I, Guglielmotti, A, Landolfi, C, Lapucci, A, Mancini, F, Milanese, C, Minutolo, F, Orlandini, E, Ortore, G, Pinza, M, Rapposelli, S. (2002) Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties. Eur. J. Med. Chem.,,  37(7),  585-594. 

DOI: 10.1016/S0223-5234(02)01385-5

 

3. Balsamo, A, Coletta, I, Domiano, P, Guglielmotti, A, Landolfi, C, Mancini, F, Milanese, C, Orlandini, E, Rapposelli, S, Pinza, M, Macchia, B. (2002) (E)-[2-(4-Methylsulphonylphenyl)-1-cyclopentenyl-1-methyliden](arylmethyloxy)amines. Methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: synthesis and biological properties. Eur. J. Med. Chem., 37(5),  391-398.

DOI: 10.1016/S0223-5234(02)01359-4

 

2. Balsamo, A, Bertini, S, Gervasi, G, Lapucci, A, Nencetti, S, Orlandini, E, Rapposelli, S, Rossello, A, Soldani, G. (2001) Enantiopure 3-(arylmethylidene)aminoxy-2-methylpropionic acids: synthesis and antiinflammatory properties. Eur. J. Med. Chem., 36(10),  799-807. 

DOI: 10.1016/S0223-5234(01)01275-2

 

1. Balsamo A, Cercignani G, Gentili D, Lapucci A, Macchia M, Orlandini E, Rapposelli S, Rossello A. (2001)   Synthesis and inhibitory activity towards human leukocyte elastase of new 7a -methoxy and 7a -chloro(2-acyloxymethyl)cephem derivatives. Eur. J. Med. Chem., 36(2),  185-193.

DOI: 10.1016/S0223-5234(01)01211-9

​